MedAvail sells SpotRx pharmacy assets to CVS Pharmacy
MedAvail, a technology-enabled pharmacy company that provide turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, has entered into a definitive agreement with CVS Pharmacy, for the sale of certain assets of MedAvail’s SpotRx pharmacies.
MedAvail has agreed to sell to CVS certain assets related to its SpotRx pharmacies located in Tucson and Phoenix, Ariz.; Buena Park, Laguna Hills and San Fernando, Calif.; Southfield, Mich. and in Orlando and Tampa, Fla. Upon completion of the CVS Transaction, the pharmacy records and inventory purchased by CVS will be transferred from the SpotRx pharmacies to nearby CVS Pharmacy locations.
[Read more: CVS Health report highlights need for expanded role of retail pharmacists]
The CVS transaction allows for the continuity of care for SpotRx pharmacy customers. To help ensure continuity of care and a seamless transition, the company plans to interview employees currently working at SpotRx pharmacies who are interested in joining its team, MedAvail said.
A portion of the proceeds from the CVS transaction will be used to pay down the company’s existing loan facility. The company previously prepaid a portion of the loan at the end of 2022, and after the closing of the transaction, the company anticipates its remaining debt balance to be approximately $2.5 million. The remaining proceeds will be used for the ongoing operation of the company, MedAvail said.
The company currently estimates that it will end 2022, prior to the CVS transaction, with between $10 million to $11 million of cash and investments. The company also currently estimates that it will incur one-time costs in the first half of 2023 related to the previously announced restructuring to be approximately $6.5 million, excluding the paydown of its existing loan facility. MedAvail continues to closely evaluate various financings options, including with existing shareholders.
[Read more: CVS Health launches HERe, Healthier Happens Together]
“We are pleased with the non-dilutive capital that we are able to generate with this agreement to extend our cash runway and reduce our debt. This divestiture is a critical step toward our path to profitability as we redeploy this capital toward the expansion of our pharmacy technology business,” said Mark Doerr, CEO of MedAvail. “I want to express my gratitude to our team members and to the CVS team for their strong commitment to our patients and focus on the continuity of care for SpotRx customers.”
The closing of the CVS transaction is expected to be completed in the first quarter of 2023. Triavo Health acted as the exclusive financial advisor for the transaction.